Is AOD-9604 Legal in Colorado?

What AOD-9604 Actually Is

AOD-9604 is a synthetic 16-amino-acid fragment of human growth hormone (hGH), specifically the C-terminal segment spanning residues 176 to 191. The peptide was originally developed by Monash University researchers to replicate the fat-metabolizing activity of hGH without stimulating IGF-1 or promoting cell proliferation.

Mechanism and Early Clinical Work

Early-phase human trials conducted in Australia tested oral AOD-9604 for obesity management. A randomized, placebo-controlled trial published in the International Journal of Obesity found that oral AOD-9604 at 1 mg/day produced modest but statistically significant weight reduction over 12 weeks compared with placebo [1]. The compound received FDA "Generally Recognized as Safe" (GRAS) status for use as a food ingredient in 2014, a designation that applies narrowly to that specific use context and does not constitute drug approval [2].

No FDA Drug Approval Exists

AOD-9604 has never received FDA approval as a drug under the New Drug Application (NDA) or Biologics License Application (BLA) pathway [3]. That single fact drives nearly every downstream legal question about access in Colorado and every other state.

The Federal Regulatory Framework

Understanding AOD-9604's legal status starts at the federal level, because federal law sets the ceiling that state rules cannot exceed.

DEA Scheduling

The Controlled Substances Act (CSA) schedules substances based on abuse potential, accepted medical use, and dependence liability [4]. AOD-9604 appears on none of the five DEA schedules. Possession of an unscheduled, non-approved drug is not a DEA offense for private individuals, though it can become a problem for practitioners who prescribe it outside accepted standards of care.

FDA's Bulk Substances List and 503A Compounding

Section 503A of the Federal Food, Drug, and Cosmetic Act (FD&C Act) allows state-licensed compounding pharmacies to prepare individualized preparations for specific patients when a valid prescription exists [5]. The catch is that the active pharmaceutical ingredient (API) must appear on FDA's approved bulk substances list, or must have been nominated and not yet rejected, or must meet other narrow criteria.

The FDA published its final guidance on bulk drug substances that may be used in compounding under section 503A in a series of Federal Register notices [6]. AOD-9604 was nominated for the 503A bulk list but was placed on the list of substances that raise significant safety, effectiveness, or compounding-need concerns. Pharmacies operating under 503A may not legally compound it for patient dispensing under current FDA policy [6].

503B Outsourcing Facilities

Section 503B of the FD&C Act created a separate category of "outsourcing facilities" that can compound larger batches without patient-specific prescriptions [7]. The 503B bulk substances list is even more restrictive than 503A. AOD-9604 does not appear on the FDA-approved 503B bulk list [7]. That effectively closes the main commercial compounding channel used by telehealth peptide prescribers.

Research Use Exception

Investigators conducting FDA-authorized clinical research can obtain AOD-9604 under an Investigational New Drug (IND) application [8]. Patients enrolled in an IRB-approved trial at a Colorado academic center or hospital could receive AOD-9604 legally in that context. Outside of a formal IND, no research-use exemption protects routine clinical prescribing.

Colorado State Law

Colorado does not add an independent layer of criminalization for AOD-9604, but state law does shape how practitioners and pharmacies must behave.

Colorado Controlled Substances Act

Colorado's Controlled Substances Act (C.R.S. § 18-18-204) mirrors the federal DEA schedules closely and adopts federal scheduling by reference for substances the DEA regulates [9]. Because AOD-9604 is not federally scheduled, it does not appear on Colorado's state schedule either. Possession by a private individual is not a state criminal offense.

Colorado State Board of Pharmacy

The Colorado State Board of Pharmacy (CSBP) licenses pharmacies and enforces state compounding regulations under C.R.S. § 12-280-101 et seq. [10]. Colorado compounding rules require compliance with USP standards and, critically, require that APIs used in compounding be sourced appropriately and comply with federal bulk-substances requirements [10]. Because the FDA has flagged AOD-9604 for 503A concerns, a Colorado-licensed 503A pharmacy that compounds it risks CSBP disciplinary action and potential FDA enforcement.

The Medical Practice Act

Colorado's Medical Practice Act (C.R.S. § 12-240-101 et seq.) governs physician prescribing [11]. Physicians hold broad authority to prescribe drugs for off-label purposes, but prescribing a substance that cannot be legally compounded or dispensed creates a practical dead end. A prescription for an ingredient that no licensed pharmacy can legally fill is not actionable by the patient.

The table below summarizes the three-layer legal test a Colorado provider must pass before prescribing AOD-9604.

| Layer | Governing Authority | AOD-9604 Status | |---|---|---| | DEA scheduling | Federal CSA | Not scheduled, no criminal bar | | FDA compounding eligibility | FD&C Act 503A/503B | Not on approved bulk list, compounding restricted | | State pharmacy compliance | CSBP / C.R.S. § 12-280 | Mirrors federal rules, compounding restricted | | Physician prescribing authority | CO Medical Practice Act | Permitted in principle; filling the Rx is the barrier |

Why AOD-9604 Ended Up in the Gray Zone

The FDA's approach to peptide compounding tightened substantially between 2019 and 2023. The agency published a bulk-substance evaluation framework that considers whether a nominated compound has clinical evidence of effectiveness, whether safety data are adequate, and whether a clinical need exists that approved drugs cannot meet [12].

The 2023 and 2024 FDA Guidance on Peptides

In 2023, the FDA issued guidance specifically addressing bulk drug substances used in compounding, reinforcing that peptides not on the approved list cannot be compounded under 503A [6]. The agency cited insufficient clinical evidence of effectiveness for most nominated peptides and concerns about quality standards for APIs manufactured outside current Good Manufacturing Practice (cGMP) facilities [6].

IGF-1 and Growth-Axis Concerns

Although AOD-9604 was designed to avoid IGF-1 stimulation, the FDA's general concern with hGH-fragment peptides includes the theoretical risk of off-target growth-axis effects with long-term use. A 2021 review in Frontiers in Endocrinology noted that the long-term safety profile of synthetic hGH fragments in humans remains inadequately characterized, particularly regarding receptor cross-reactivity at supraphysiologic doses [13]. That evidence gap contributed to the FDA's reluctance to approve AOD-9604 for the 503A bulk list.

GRAS Status Does Not Mean Drug-Legal

The FDA's 2014 GRAS determination for AOD-9604 as a food ingredient is frequently misread as broad regulatory approval [2]. GRAS designation under 21 C.F.R. § 170.30 addresses safety for a specific food use at a specific dose; it says nothing about the compound's status as a drug ingredient [2]. The FDA has explicitly stated that a GRAS determination for food use does not affect the agency's ability to regulate the same substance as a drug [2].

How to Get AOD-9604 in Colorado Legally

Several access routes exist, each with different risk profiles.

Route 1: IND-Authorized Clinical Trial

The only completely unambiguous route is enrollment in an FDA-authorized clinical trial. ClinicalTrials.gov lists studies involving AOD-9604; patients in Colorado can search by zip code and contact the principal investigator directly [8]. Participation requires meeting inclusion criteria, informed consent, and ongoing monitoring.

Route 2: 503B Outsourcing Facility With Compounding Authority

A small number of 503B outsourcing facilities have applied for or obtained specific authorizations to compound certain peptides under conditions negotiated with the FDA. If a 503B facility obtains explicit authorization and AOD-9604 is added to an approved bulk list through rulemaking, Colorado physicians could prescribe it and the facility could fill the order. That scenario has not occurred as of the July 2025 review date, but regulatory status can change. Providers should check the FDA's current 503B bulk list before prescribing [7].

Route 3: Research-Use Agreement Through an Academic Center

Some Colorado academic medical centers, including programs affiliated with the University of Colorado Anschutz Medical Campus, have institutional frameworks for accessing investigational compounds under physician-sponsored INDs. A board-certified endocrinologist or obesity medicine specialist can sponsor an IND for a single patient in compelling circumstances, though the process takes months and requires IRB review.

Routes to Avoid

Purchasing AOD-9604 from unregulated online vendors is common but legally and medically problematic. Products sold as "research chemicals" are not manufactured under cGMP, have no certificate of analysis from an accredited third-party lab, and may contain the wrong peptide sequence, incorrect concentrations, or microbial contamination [14]. The FDA has issued warning letters to peptide vendors selling products not compliant with federal law [14]. Colorado patients who use such products assume both a safety risk and a risk that their physician cannot properly supervise dosing.

What Colorado Clinicians Should Know

Prescribing physicians in Colorado face specific professional risks when engaging with AOD-9604 outside of an IND.

Liability Under Standard of Care

The standard of care in obesity medicine and endocrinology is increasingly defined by evidence-based guidelines. The Endocrine Society's 2024 clinical practice guideline on obesity pharmacotherapy does not include AOD-9604 as a recommended agent [15]. Prescribing a compound absent from guidelines, unavailable from licensed pharmacies, and lacking an approved indication exposes a Colorado physician to disciplinary review by the Colorado Medical Board.

Documentation Requirements

If a Colorado physician does prescribe AOD-9604 through a legitimate investigational channel, complete documentation is required: the rationale for use, the absence of approved alternatives, the patient's informed consent covering off-label status and the limitations of safety data, and the source of the compounded or investigational product. The American Academy of Family Physicians recommends that physicians document off-label prescribing rationale thoroughly as a standard of risk management [16].

When AOD-9604 Competes With Approved Options

Colorado patients seeking weight management have access to FDA-approved agents with strong efficacy data. Semaglutide 2.4 mg (Wegovy) produced 14.9% mean body weight loss at 68 weeks in the STEP-1 trial (N=1,961, P<0.001 vs. Placebo) [17]. Tirzepatide 15 mg (Zepbound) produced 20.9% mean body weight loss at 72 weeks in SURMOUNT-1 (N=2,539, P<0.001 vs. Placebo) [18]. These approved options carry defined safety profiles, FDA-regulated manufacturing, and insurance coverage pathways that AOD-9604 cannot currently match.

Regulatory Outlook: Could the Status Change?

The FDA's bulk-substances rulemaking is ongoing. Interested parties can nominate substances for the 503A list, and the FDA reviews nominations on a rolling basis [6]. If new clinical evidence demonstrates sufficient efficacy and safety for AOD-9604, a successful nomination could reopen the compounding pathway. The compound's existing GRAS safety record for oral use may support a future nomination for a narrowly defined compounded injectable indication. Advocates within the peptide therapy community have submitted comments to the FDA docket supporting reconsideration [6].

The Endocrine Society's position on off-label peptides, summarized in a 2022 statement, is that "compounded peptides should meet the same evidentiary standards as approved drugs before widespread clinical adoption" [15]. That standard has not yet been met for AOD-9604 in the injectable weight-loss context.

Patients and providers should monitor the FDA's 503A bulk-substances docket (Docket No. FDA-2013-N-1525) for updates, as any addition of AOD-9604 to the approved list would immediately change the legal field for Colorado compounding pharmacies [6].